First live-cell imaging system in China will be used for drug discovery programme, and the first-ever high content screening (HCS) workshop will be held in Shanghai in April 2005
Affiliated with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, the National Center for Drug Screening (NCDS) is a key national technology innovation base in drug discovery and development.
NCDS has completed its high content screening (HCS) portfolio of research and discovery tools with the acquisition of a KineticScan HCS reader, Cellomics's premier instrument for performing live-cell, kinetic HCS assays.
The second part of this expansion includes the organisation and sponsorship of a nationwide HCS workshop to be held at the NCDS in Shanghai, on 4-6 April 2005.
This event will bring together 60 researchers selected from more than 20 major cities, provinces and autonomous regions, who are looking to bring HCS capabilities into their drug discovery and systems biology research programs.
"The adoption of Cellomics's live-cell imaging system, the KineticScan HCS Reader, is vital to expanding our research programmes in cell-based high content screening," said Ming-Wei Wang, director of the NCDS.
"By adding the capabilities of the KineticScan to those we already have with Cellomics's ArrayScan HCS reader, we are able to quickly execute our strategic plan of utilising HCS technologies in our drug discovery and development efforts".
"We are very excited to work with the NCDS to organise the first-ever HCS workshop in China.
"Cellomics has been performing HCS workshops and user group meetings in the USA for many years, and we are happy to be able to share our expertise in this area with drug discovery and research scientists in China," said Judy Masucci, director of marketing at Cellomics.
"We are pleased to be able to send three of our top HCS experts to support this event".
"Our collaboration with Dr Wang and the NCDS is critically important for Cellomics," commented Daniel Calvo, President and CEO of Cellomics.
"Through this joint effort with China's leading drug discovery facility, we can expand our global leadership position in HCS into China and the surrounding region.
"We look forward to continuing to assist this world-class laboratory in incorporating our technologies into their research programmes, as well as supporting the expansion of HCS across China," continued Calvo.